- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06016842
원발성 담즙성 담관염 성인 참가자를 대상으로 한 Elafibranor에 대한 장기 연구 (ELFIDENCE)
원발성 담즙성 담관염(PBC)이 있는 성인 참가자의 장기 임상 결과에 대한 Elafibranor 80mg의 효능과 안전성을 평가하기 위한 무작위 배정, 병렬 그룹, 이중 맹검, 위약 대조, 양군 연구 3상
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver).
PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage.
The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.
This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment) and will last up to 3.5 years for each participant.
The main aim of this study is to determine if elafibranor is better than placebo in preventing clinical outcome events showing disease worsening (including progression of disease leading to liver transplant or death).
This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Ipsen Clinical Study Enquiries
- 전화번호: See e mail
- 이메일: clinical.trials@ipsen.com
연구 장소
-
-
-
Athens, 그리스
- 모병
- General Hospital of Athens Laiko
-
Athens, 그리스
- 모병
- General Oncological Hospital of Kifisia Oi Agioi Anargyroi
-
Athens, 그리스
- 모병
- Agios Savvas Regional Cancer Hospital
-
Thessaloniki, 그리스
- 모병
- GeneIppokratio General Hospital of Thessaloniki
-
-
-
-
-
Christchurch, 뉴질랜드
- 모병
- Canterbury District Health Board
-
Hamilton, 뉴질랜드
- 모병
- Waikato Hospital
-
-
-
-
-
Bucheon-si, 대한민국
- 모병
- Soon Chun Hyang University Bucheon Hospital
-
Busan, 대한민국
- 모병
- Pusan National University Hospital (PNUH)
-
Daegu, 대한민국
- 모병
- Keimyung University Dongsan Hospital
-
Daejeon, 대한민국
- 빼는
- The Catholic University of Korea Daejeon St.Mary's Hospital
-
Goyang-si, 대한민국
- 모병
- Inje University Ilsan Paik Hospital
-
Gyeonggi-do, 대한민국
- 빼는
- Korea University Ansan Hospital
-
Incheon, 대한민국
- 모병
- Inha University Hospital
-
Junggu, 대한민국
- 모병
- Kyungpook National University Hospital (KNUH)
-
Seongnam-si, 대한민국
- 모병
- CHA Bundang Medical Center, CHA University
-
Seoul, 대한민국
- 모병
- Samsung Medical Center
-
Seoul, 대한민국
- 모병
- Seoul National University Hospital
-
Seoul, 대한민국
- 모병
- Korea University Guro Hospital
-
Seoul, 대한민국
- 빼는
- Hallym University Kangnam Sacred Heart Hospital
-
Seoul, 대한민국
- 모병
- Seoul National University Bundang Hospital (SNUBH)
-
Seoul, 대한민국
- 모병
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital
-
Seoul, 대한민국
- 모병
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, 대한민국
- 모병
- Hanyang University Seoul Hospital
-
Seoul, 대한민국
- 빼는
- Chung-Ang University Hospital
-
Seoul, 대한민국
- 종료됨
- Severance Hospital, Yonsei University Health System
-
Uijeongbu-si, 대한민국
- 모병
- The Catholic University of Korea, Uijeongbu St. Mary's Hospital
-
-
-
-
-
Copenhagen, 덴마크
- 모병
- Bispebjerg Hospital
-
-
-
-
-
Bucharest, 루마니아
- 모병
- Centrul Pentru Studiul Metabolismului
-
Bucharest, 루마니아
- 모병
- Sana S.R.L
-
Bucharest, 루마니아
- 모병
- Spital Clinic Dr I Cantacuzino
-
Cluj-Napoca, 루마니아
- 모병
- Cluj County Clinical Emergency Hospital
-
Cluj-Napoca, 루마니아
- 모병
- Spitalul Clinic De Urgenta Prof. Dr. Octavian Fodor
-
Iași, 루마니아, 700111
- 모병
- Gastromedica Srl
-
-
-
-
-
Kaunas, 리투아니아
- 모병
- Hospital of Lithuanian University of Health Sciences Kaunas
-
Vilnius, 리투아니아
- 모병
- Vilnius University Hospital Santaros Klinikos
-
-
-
-
-
Johor Bahru, 말레이시아
- 모병
- Hospital Sultanah Aminah
-
Kota Kinabalu, 말레이시아
- 모병
- Hospital Queen Elizabeth II
-
Kuala Lumpur, 말레이시아
- 모병
- University of Malaya Medical Centre
-
-
-
-
-
Guadalajara, 멕시코
- 모병
- Centro de Investigacion Clinica y Medicina Traslacional
-
Jalisco, 멕시코
- 모병
- Centro de Investigacion Medico Biologica y Terapia Avanzada
-
Mexico City, 멕시코
- 모병
- Centro de Investigacion y Gastroenterologia SC
-
Mexico City, 멕시코
- 모병
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ)
-
Monterrey, 멕시코
- 모병
- Hospital Angeles Valle Oriente
-
Yucatán, 멕시코
- 모병
- Medical Care & Research
-
-
-
-
Arizona
-
Tucson, Arizona, 미국, 85641
- 모병
- Arizona Liver Health
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 55130
- 종료됨
- Arkansas Diagnostic Center, PA
-
-
California
-
Coronado, California, 미국, 92118
- 모병
- Southern California Research Center
-
Los Angeles, California, 미국, 90048
- 빼는
- Cedars-Sinai Medical Center
-
Los Angeles, California, 미국, 90404
- 빼는
- University of California Los Angeles
-
Los Angeles, California, 미국, 90067
- 모집하지 않고 적극적으로
- GastroIntestinal BioSciences
-
Sacramento, California, 미국, 95817
- 모병
- University of California Davis Medical Center
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- University of Colorado
-
Colorado Springs, Colorado, 미국, 80829
- 모병
- Peak Gastroenterology Associates
-
Englewood, Colorado, 미국, 80113
- 모집하지 않고 적극적으로
- South Denver Gastroenterology, P.C.
-
Littleton, Colorado, 미국, 80120
- 모병
- Rocky Mountain Gastroenterology
-
-
Florida
-
Miami, Florida, 미국, 33136
- 모병
- University Of Miami School Of Medicine, Center For Liver Diseases
-
Pembroke Pines, Florida, 미국, 12105
- 모병
- Bolanos Clinical Research
-
Tampa, Florida, 미국, 33614
- 모병
- International Center for Research
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 아직 모집하지 않음
- University of Kansas Medical Center (KUMC) - University of Kansas Liver Center - Hepatology Clinic
-
-
Louisiana
-
Shreveport, Louisiana, 미국, 71103
- 모병
- Louisiana Research Center, LLC
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan Health System
-
Ypsilanti, Michigan, 미국, 48197
- 빼는
- Huron Gastroenterology Associates - Center for Digestive Care
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87109
- 종료됨
- Southwest Gastroenterology Associates, PC (SWGA)
-
-
New York
-
New York, New York, 미국, 10016
- 모병
- NYU Langone Gastroenterology and Hepatology Associates
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- 모병
- University of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 모병
- Medical University of South Carolina
-
-
Tennessee
-
Cordova, Tennessee, 미국, 38138
- 모병
- Gastroenterology Center of the Midsouth
-
-
Texas
-
Arlington, Texas, 미국, 22201
- 모병
- Texas Clinical Research Institute
-
Austin, Texas, 미국, 78757
- 모병
- American Research Corporation
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern Medical Center at Dallas
-
Dallas, Texas, 미국, 75203
- 모병
- Methodist Transplant Physicians
-
Dallas, Texas, 미국, 60612
- 빼는
- Rush University Medical Center - University Cardiovascular Surgeons
-
Dallas, Texas, 미국, 75203
- 종료됨
- Liver Center of Texas
-
Fort Worth, Texas, 미국, 76104
- 빼는
- Baylor Scott & White All Saints Medical Center - Forth Worth
-
Houston, Texas, 미국, 77030
- 모병
- Liver Associates of Texas
-
Houston, Texas, 미국, 77584
- 모집하지 않고 적극적으로
- Houston Methodist Cancer Center
-
Katy, Texas, 미국, 77904
- 종료됨
- Gastro health & Nutrition
-
San Antonio, Texas, 미국, 78015
- 모병
- American Research Corporation at The Texas Liver Institute
-
San Antonio, Texas, 미국, 78251
- 모병
- Starhope Liver Center, PA - Starhope Clinical Research, LLC
-
Waco, Texas, 미국, 76710
- 빼는
- Impact Research Tx
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- 모병
- University of Virginia Medical Center
-
Richmond, Virginia, 미국, 23298
- 아직 모집하지 않음
- Virginia Commonwealth University Medical Center - West Hospital
-
Richmond, Virginia, 미국, 23226
- 모병
- Bon Secours St. Mary's Hospital of Richmond, Inc
-
-
Washington
-
Columbia, Washington, 미국, 20007
- 빼는
- Medstar Georgetown Transplant Institute University Hospital (MGUH)
-
Seattle, Washington, 미국, 98105
- 모병
- Velocity Clinical Research at Liver Institute Northwest
-
-
West Virginia
-
Huntington, West Virginia, 미국, 25701
- 모병
- University Physicians and Surgeons Inc, dba Marshall Health
-
-
-
-
-
Edegem, 벨기에
- 빼는
- Universitair Ziekenhuis Antwerpen
-
Genk, 벨기에
- 빼는
- Ziekenhuis Oost-Limburg
-
Ghent, 벨기에
- 모병
- Gent University Hospital
-
Roeselare, 벨기에
- 빼는
- Algemeen Ziekenhuis Delta
-
-
-
-
-
Sofia, 불가리아
- 모병
- Tokuda Hospital, Dept. of Internal Medicine
-
Sofia, 불가리아
- 모병
- University Hospital City Clinic Cancer Center
-
Sofia, 불가리아
- 모집하지 않고 적극적으로
- Diagnostic-Consultative Center Aleksandrovska EOOD
-
-
-
-
-
Belo Horizonte, 브라질
- 모병
- NUPEC Cardio
-
Goiânia, 브라질
- 모병
- Universidade Federal de Goias
-
Porto Alegre, 브라질
- 모병
- Hospital de Clinicas de Porto Alegre (HCPA)
-
Salvador, 브라질
- 모병
- Instituto D'Or de Pesquisa e Ensino - Hospital Aliança
-
São Paulo, 브라질
- 모병
- Hospital de Base - Centro Integrado de Pesquisa ( CIP )
-
São Paulo, 브라질
- 모병
- Universidade Estadual Paulista Julio De Mesquita Filho (UNESP) Hospital das Clinicas Faculdade de Medicina de Botucatu (HCFMB)
-
São Paulo, 브라질
- 모병
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
-
-
-
-
-
Barcelona, 스페인
- 모병
- Hospital Universitario Vall d'Hebron
-
Barcelona, 스페인
- 모병
- Hospital Clinic i Provincial de Barcelona
-
Madrid, 스페인
- 빼는
- Hospital Universitario La Paz
-
Madrid, 스페인
- 모병
- Clinica Universidad Navarra-Sede Madrid
-
Madrid, 스페인
- 모집하지 않고 적극적으로
- Hospital General Universitario Gregorio Maranon (HGUGM)
-
Majadahonda, 스페인
- 모병
- Hospital Universitario Puerta de Hierro de Majadahonda
-
Málaga, 스페인
- 모병
- Hospital Universitario Virgen de la Victoria
-
Pontevedra, 스페인
- 모병
- Hospital De Montecelo
-
Sabadell, 스페인
- 모집하지 않고 적극적으로
- Institut d Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Tauli
-
Seville, 스페인
- 모병
- Hospital Universitario Virgen del Rocio
-
Valencia, 스페인, 46026
- 종료됨
- Hospital Universitario y Politecnico La Fe
-
Valladolid, 스페인
- 빼는
- Hospital Universitario Rio Hortega
-
Zaragoza, 스페인
- 모병
- Hospital Universitario Miguel Servet
-
-
-
-
-
Bratislava, 슬로바키아
- 모병
- Gastroenterological Centre Thalion
-
Košice, 슬로바키아
- 모병
- Univerzitna nemocnica L. Pasteura Kosice
-
Nitra, 슬로바키아
- 모병
- Fakultna nemocnica Nitra
-
-
-
-
-
Buenos Aires, 아르헨티나
- 모병
- Hospital Italiano de Buenos Aires
-
Buenos Aires, 아르헨티나
- 모병
- Fundacion Respirar (Centro Medico Dra. De Salvo) - Instituto Argentino de Investigaciones Clinicas (IAIC) S.R.L
-
Buenos Aires, 아르헨티나
- 모병
- DIM Centro Medico
-
Buenos Aires, 아르헨티나
- 모병
- Hospital Britanico de Buenos Aires
-
Córdoba, 아르헨티나
- 모병
- Centro Medico Colon
-
Mendoza, 아르헨티나
- 빼는
- Hospital Espanol de Mendoza
-
Pilar, 아르헨티나
- 모병
- Hospital Universitario Austral
-
San Juan Bautista, 아르헨티나
- 모병
- Hospital El Cruce
-
-
-
-
-
Beersheba, 이스라엘
- 빼는
- Institute of Gastroenterology and Liver Diseases - Soroka University Medical Center
-
Haifa, 이스라엘
- 빼는
- Rambam Health Care Campus (RHCC)
-
Jerusalem, 이스라엘
- 종료됨
- Hadassah University Hospital (HUH) - Ein-Kerem
-
Jerusalem, 이스라엘
- 종료됨
- Shaare Zedek Medical Center
-
Nahariya, 이스라엘
- 종료됨
- Galilee Medical Center
-
Nahariya, 이스라엘
- 빼는
- Galilee Medical Center, ZIV Medical Center
-
Petah Tikva, 이스라엘
- 빼는
- Rabin Medical Center - Beilinson Hospital - Liver Institute
-
-
-
-
-
Modena, 이탈리아
- 빼는
- Azienda Ospedaliero Universitaria Modena
-
Monza, 이탈리아
- 모집하지 않고 적극적으로
- Ospedale San Gerardo
-
Naples, 이탈리아
- 종료됨
- Azienda Ospedaliero Universitaria Federico II di Napoli
-
Padova, 이탈리아
- 빼는
- Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia
-
Palermo, 이탈리아
- 종료됨
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
Pavia, 이탈리아
- 빼는
- Fondazione I.R.C.C.S. Policlinico San Matteo
-
Pisa, 이탈리아
- 빼는
- Azienda Ospedaliero Universitaria Pisana
-
San Giovanni Rotondo, 이탈리아
- 빼는
- Ospedale Casa Sollievo della Sofferenza
-
-
-
-
-
Hradec Králové, 체코
- 모병
- Hepato-Gastroenterologie HK, s.r.o.
-
Liberec, 체코
- 빼는
- Krajska Nemocnice Liberec
-
Ostrava, 체코
- 모병
- Artroscan
-
Pilsen, 체코
- 모병
- Research Site s.r.o.
-
Prague, 체코
- 모병
- Institute for Clinical and Experimental Medicine - IKEM
-
-
-
-
-
Las Condes, 칠레
- 모병
- Universidad De Los Andes
-
Santiago, 칠레
- 모병
- Enroll SpA
-
Santiago, 칠레
- 모병
- Centro de Estudios Clinicos e Investigaciones Medicas (CECIM)
-
Santiago, 칠레
- 모병
- Hospital Clinico de la Pontificia Universidad Catolica de Chile
-
Santiago, 칠레
- 모병
- University of Chile Clinical Hospital (Hospital Clinico de la Universidad de Chile)
-
Viña del Mar, 칠레
- 모병
- Centro Medico Cedid - Centro de Diagnostico Digestivo
-
-
-
-
-
Edmonton, 캐나다
- 모병
- University of Alberta - Faculty of Medicine & Dentistry - The Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)
-
Toronto, 캐나다
- 모병
- University Health Network (UHN) - Toronto General Hospital (TGH) - Toronto General Research Institute (TGRI)
-
-
-
-
-
Barranquilla, 콜롬비아
- 모병
- Clinica de la Costa
-
Cali, 콜롬비아
- 모병
- Clinica Imbanaco de S.A.S.
-
Cali, 콜롬비아
- 모병
- Salud SURA Chipichape
-
Floridablanca, 콜롬비아
- 모병
- Fundacion Oftalmologica de Santander-Clinica Ardila Lulle La FOSCAL
-
Medellín, 콜롬비아
- 모병
- Hospital Pablo Tobon Uribe
-
Medellín, 콜롬비아
- 모병
- Servicios de Salud IPS Suramericana S.A.S. Industriales
-
-
-
-
-
Chiang Mai, 태국
- 모병
- Chiang Mai University
-
Hat Yai, 태국
- 모병
- Prince of Songkla University (PSU) - Songklanagarind Hospital
-
Khon Kaen, 태국
- 모병
- Srinagarind Hospital - Khon Kaen University
-
-
-
-
-
Lima, 페루
- 모병
- Clinica Delgado
-
-
-
-
-
Funchal, 포르투갈, 9004-514
- 모병
- Hospital Dr. Nelio Mendonca
-
Vila Real, 포르투갈, 5000-508
- 모병
- Unidade Local de Saúde de Trás-os-Montes e Alto Douro, E. P. E
-
-
Praceta Mota Pinto
-
Coimbra, Praceta Mota Pinto, 포르투갈
- 모병
- Hospitais da Universidade de Coimbra (H.U.C) - Universidade de Coimbra
-
-
-
-
-
Elblag, 폴란드
- 모병
- NZOZ Twoje Zdrowie EL Sp. z o.o.
-
Katowice, 폴란드
- 모병
- Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego
-
Krakow, 폴란드
- 모병
- Krakowskie Centrum Medyczne Sp.z.o.o - FutureMeds
-
Krakow, 폴란드
- 빼는
- Szpital Uniwersytecki w Krakowie
-
Lodz, 폴란드, 90-153
- 모병
- Oddzial Kliniczny Gastroenterologii Ogolnej i Onkologicznej SPZOZ, Uniwersytecki Szpital Kliniczny im. Barlickiego w Lodzi
-
Lublin, 폴란드
- 모병
- Medrise Sp. z o.o.
-
Małogoskie, 폴란드
- 아직 모집하지 않음
- Krakowskie Centrum Medyczne Sp.z.o.o. - FutureMeds
-
Rzeszów, 폴란드
- 모병
- Centrum Medyczne Medyk Sp. z o.o. Sp. K.
-
Sosnowiec, 폴란드
- 빼는
- Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ) - Poliklinika Doktora Bessera
-
Warsaw, 폴란드
- 모병
- FutureMeds Warszawa Centrum
-
Wroclaw, 폴란드
- 모병
- FutureMeds sp. z o. o
-
Wroclaw, 폴란드
- 모병
- Nzoz Centrum BadanKlinicznych
-
Wroclaw, 폴란드
- 모병
- PlanetMed Sp. z o.o.
-
-
-
-
-
Clichy, 프랑스
- 모병
- Hopital Beaujon
-
Créteil, 프랑스, 94000
- 모병
- Hospital Henri Mondor
-
Lille, 프랑스
- 빼는
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez
-
Lyon, 프랑스
- 모병
- Hospices Civils de Lyon (HCL) - Hopital de la Croix-Rousse
-
Marseille, 프랑스
- 빼는
- Hopital Saint Joseph - Marseille
-
Nice, 프랑스
- 모병
- CHU de Nice, Hopital de l'Archet
-
Paris, 프랑스, 75013
- 모병
- Hopital Pitie-Salpetriere - APHP
-
Poitiers, 프랑스
- 빼는
- CHU Poitiers
-
Toulouse, 프랑스
- 빼는
- Clinique Pasteur
-
Villejuif, 프랑스
- 빼는
- Hopital Paul-Brousse - APHP
-
-
-
-
-
Budapest, 헝가리
- 모병
- Central Hospital of Northern Pest - Military Hospital
-
Debrecen, 헝가리
- 모병
- Kenezy County Hospital
-
Szeged, 헝가리
- 모병
- Szegedi Tudomanyegyetem AOK, I. sz Belgyogyaszati Klinika
-
-
-
-
-
Birtinya, 호주
- 모병
- Sunshine Coast University Hospital
-
Footscray, 호주
- 모병
- Footscray Hospital, Western Health
-
Kingswood, 호주
- 빼는
- Nepean Clinical School
-
Melbourne, 호주
- 빼는
- Monash University - Monash Health -Monash Medical Centre
-
Sydney, 호주
- 빼는
- St George Hospital
-
Westmead, 호주
- 모병
- Westmead Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria :
- Male or female participants must be ≥18 years of age at the time of signing the informed consent.
- Participants with a definite or probable diagnosis of primary biliary cholangitis (PBC)
- Participants with cirrhosis at SV1. • Participants must be Child Pugh A or Child Pugh B.
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion Criteria :
-
History or presence of other concomitant liver disease including but not limited to:
- i) Primary sclerosing cholangitis (PSC).
- ii) Autoimmune hepatitis (AIH) by simplified Diagnostic Criteria of the International Autoimmune Hepatitis Group (IAIHG) ≥6, or if treated for an overlap of PBC with AIH, or if there is clinical suspicion and evidence of overlap AIH features, that cannot be explained alone by insufficient response to UDCA.
- iii) Positive hepatitis B surface antigen (HBsAg). Participants with negative HBsAg and positive hepatitis B core antibody (HBcAb) may be eligible if hepatitis B virus deoxyribonucleic acid (HBV DNA) is negative.
- iv) Hepatitis C virus (HCV) infection defined by positive anti-HCV antibody and positive HCV ribonucleic acid (RNA) (Note: Participants with positive anti-HCV antibody due to previously treated HCV infection, may be enrolled if a confirmatory HCV RNA is undetectable and sustained viral response has been documented).
- v) Alcohol-associated liver disease (ALD).
- vi) Nonalcoholic steatohepatitis (NASH).
- vii) Other chronic liver diseases, such as alpha-1 antitrypsin deficiency.
-
History or presence of clinically significant hepatic decompensation, including:
- i) History of liver transplantation, current placement on a liver transplant list, current model for end-stage liver disease including (MELD) 3.0 score >12 due to hepatic impairment.
- ii) Evidence of complications of cirrhosis, including hepatic decompensation or evidence of significant portal hypertension complications including presence of uncontrolled ascites; history of variceal bleeding or related interventions (e.g. variceal banding, or transjugular intrahepatic portosystemic shunt placement); presence of hepatic encephalopathy Grade 2 or higher per West-Haven criteria; history or presence of spontaneous bacterial peritonitis. Note: participants with low-risk varices (Grade I) without history of bleeding or other treatment may be eligible to enrol.
- iii) Hepatorenal syndrome (HRS) (type I or II ). • vi) Hospitalisation for liver-related complication within 12 weeks prior to SV1.
-
Known history of human immunodeficiency virus (HIV) infection or having a positive confirmatory test for HIV type 1 or 2.
-
Medical conditions that may cause non-hepatic increases in ALP (e.g. Paget's disease).
-
Evidence of any other unstable or untreated clinically significant immunological, endocrine, hematologic, gastrointestinal, neurological, or psychiatric disease as evaluated by the investigator; other clinically significant conditions that are not well controlled.
-
Non-hepatic medical conditions that may diminish life expectancy to <2 years, including known cancers.
-
History of hepatocellular carcinoma.
-
Alpha-fetoprotein (AFP) >20 ng/mL with 4-phase liver computerised tomography (CT) or magnetic resonance imaging (MRI) imaging suggesting presence of hepatocellular carcinoma.
-
Known malignancy or history of malignancy within the last 5 years. Participants with non-melanoma skin cancer, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
-
Administration of the following medications is prohibited during the study, and prior to the study as per the timelines specified below: • i) 3 months prior to baseline: fibrates, seladelpar, glitazones, obeticholic acid, azathioprine, cyclosporine, methotrexate, mycophenolate, pentoxifylline, budesonide and other systemic corticosteroids (parenteral and oral chronic administration only); potentially hepatotoxic drugs (including α-methyl-dopa, sodium valproic acid, isoniazid or nitrofurantoin).
-
Participants who are currently participating in, plan to participate in, or have participated in an investigational drug study or medical device study containing active substance within 30 days or 5 half-lives, whichever is longer, prior to the screening period.
i) If the previous study was for an experimental therapy being studied for potential benefit in PBC, and the potential therapeutic agent was proven to have no beneficial effect in PBC and there are no safety concerns, the participant may enrol after 30 days or 5 half-lives from the last dose of the therapeutic agent, whichever is longer.ii) For therapeutic agents being studied for potential benefit in PBC for which it is still unclear if there may be a potential benefit, participants may enrol after 6 months from the last dose of the therapeutic agent.
-
Electrocardiogram (ECG) with QT interval corrected by Fridericia's formula (QTcF) >450 msec in males or QTcF >470 msec in females for participants without bundle branch block. For participants with bundle branch block or other intraventricular conduction delay, a longer QTcF >480 msec would be exclusionary.
-
Total bilirubin (TB) >5x ULN
-
Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >5x ULN at SV1
-
Creatinine phosphokinase (CPK) >2x ULN.
-
Platelet count <50,000/μL
-
International normalised ratio (INR) >1.8 in the absence of anticoagulant therapy.
-
Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m2 per the Modification of Diet in Renal Disease (MDRD)-6 Study formula at SV1.
-
Significant renal disease, including nephritic syndrome, chronic kidney disease (CKD) (defined as participants with evidence of significantly impaired kidney function or underlying kidney injury).
-
For female participants: known current pregnancy, or has a positive serum pregnancy test, or is breastfeeding.
-
Participants unwilling or unable to be abstinent from alcohol during the study.
-
History of alcohol abuse, or other substance abuse within 1 year prior to SV1.
-
Known hypersensitivity to elafibranor or to any of the excipients of the investigational product(s).
-
Mental instability or incompetence, such that the validity of informed consent or ability to be compliant with the study is uncertain.
-
Any other condition that, in the opinion of the investigator, would interfere with study participation or completion, or would put the participant at risk, including a potential participant assessed as being at high risk of noncompliance with the study.
-
Alkaline phosphatase (ALP) ≥10x ULN.
-
Albumin <2.8 g/dL due to impaired hepatic function.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Elafibranor 80 mg
Participants will take 1 tablet of elafibranor 80 mg per day orally with a glass of water at approximately the same time each morning, with or without food. |
Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily |
|
위약 비교기: Placebo
Participants will take 1 placebo tablet per day orally (matching the 80 mg elafibranor sized tablet) with a glass of water at approximately the same time each morning, with or without food. |
Duration: up to an estimated 42-month (3.5-year) double-blind treatment period during which matching placebo tablet will be administered once daily |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Event-free survival
기간: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
Event-free survival is defined as the time from randomisation to either adjudicated disease progression or death, whichever occurs first. |
From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
0~24시간의 혈장 농도-시간 곡선 아래 면적: AUC0-24
기간: 1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
|
|
최대(피크) 혈장 약물 농도: Cmax
기간: 1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
|
|
약물 투여 후 최대(피크) 혈장 농도에 도달하는 시간): Tmax
기간: 1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
|
|
혈장에서 약물의 명백한 제거(CL)
기간: 1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
|
|
겉보기 분포량(VZ)
기간: 1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
1일차/기준일, 6개월차 및 12개월차(24시간 투여 기간 동안)
|
|
|
알칼리성 포스파타제(ALP)의 기준선 대비 변화
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
총 빌리루빈(TB) 기준치 대비 변화
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
ALP ≤ 1.67x ULN 및 TB ≤ ULN인 참가자의 비율
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
알부민 표준화에 기초한 반응을 보이는 참가자의 비율
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
기준선과 비교한 아스파르테이트 아미노트랜스퍼라제(AST)의 혈청 수준 변화
기간: 12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
기준선과 비교한 ALT의 혈청 수준 변화
기간: 12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
기준선과 비교한 감마-글루타밀 전이효소(GGT)의 혈청 수준 변화
기간: 12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
기준선과 비교한 알부민의 혈청 수준 변화
기간: 12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
간 기능의 기준선 대비 변화: 국제 표준화 비율(INR)
기간: 12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
간 기능의 기준선 대비 변화: 분류된 ALP
기간: 12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
12개월째 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
ALP가 40% 감소한 참가자 비율
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
ALP <1.5x ULN, ALP 감소 ≥15% 및 TB ≤ULN인 참가자의 비율
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
ALP <1.5x ULN, ALP 감소 ≥40% 및 TB ≤ULN인 참가자의 비율
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
ALP <1.67x ULN, ALP 감소 ≥15% 및 TB ≤ULN인 참가자의 비율
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
ALP <3x ULN, AST <2x ULN 및 TB ≤1mg/dL인 참가자의 비율(파리 I)
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
ALP가 1.5x ULN 이하, AST가 1.5x ULN 및 TB가 1mg/dL 이하인 참가자의 비율(파리 II 기준)
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
비정상 결핵이 정상화된 참가자 비율
기간: 6개월차, 12개월차, 그리고 치료 종료 시까지 12개월마다 평가(최대 기간 3.5년)
|
6개월차, 12개월차, 그리고 치료 종료 시까지 12개월마다 평가(최대 기간 3.5년)
|
|
|
비정상 결핵 및 알부민이 정상화된 참가자 비율(로테르담 기준)
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
지질 매개변수의 기준선 대비 변화: 총 콜레스테롤(TC)
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
지질 매개변수의 기준선 대비 변화: 고밀도 지질단백질 콜레스테롤(HDL-C)
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
지질 매개변수의 기준선 대비 변화: 저밀도 지질단백질 콜레스테롤(LDL-C)
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
지질 매개변수의 기준선 대비 변화: 트리글리세리드(TG)
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
지질 매개변수의 기준선 대비 변화: 초저밀도 지질단백질 콜레스테롤(VLDL-C) 계산
기간: 6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
6개월, 12개월 및 치료 종료 시까지 12개월마다(최대 3.5년)
|
|
|
Change from baseline in hepatic function: Conjugated (direct) bilirubin
기간: At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
|
Percentage of participants with ALP reduction >40% or ALP normalisation (Barcelona criteria)
기간: At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
|
Percentage of participants with TB ≤0.6× ULN in participants with TB >0.6× ULN at baseline
기간: At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
|
Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs), treatment-related TEAEs, Serious Adverse Events (SAEs), and Adverse Events of Special Interests (AESIs)
기간: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
An adverse event (AE) is any unfavourable medical occurrence in a trial participant administered the investigational product. The AE does not necessarily have a causal relationship with the treatment. AESIs are AEs that may or may not be serious but are of special importance to a particular drug or class of drugs. |
From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
|
Percentage of participants developing clinically significant changes in physical examination findings
기간: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
Complete physical examination at screening and targeted examination at all other clinical visit timepoints. |
From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
|
Percentage of participants developing clinically significant changes in vital signs
기간: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
Percentage of participants with clinically significant changes in Vital Signs will be reported. The clinical significance will be graded by the investigator. |
From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
|
Percentage of participants developing clinically significant changes in Electrocardiogram (ECG) readings.
기간: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
Percentage of participants with clinically significant changes in ECG readings will be reported. The clinical significance will be graded by the investigator. |
From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
|
Percentage of participants with clinically significant changes in laboratory parameters (blood chemistry, hematology, coagulation and urinalysis)
기간: From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be graded by the investigator. |
From baseline until 4 weeks after the last dose of study intervention (maximum duration of 3.5 years)
|
|
Percentage of participants with complete biochemical response
기간: At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
Defined as normal levels of TB, ALP, transaminases, albumin, and International normalised ratio (INR) |
At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Percentage of participants with normalisation of TB and ALP
기간: At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
Defined as TB< Upper Limit Normal (ULN) and ALP< ULN |
At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Percentage of participants with stabilisation in TB (i.e. no increase)
기간: At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
Defined as TB< 1x ULN or increase from baseline <0.1x ULN |
At Month 6, Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in liver stiffness measurement (LSM)
기간: At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
Assessed by vibration-controlled transient elastography (VCTE) using Fibroscan® on the day of the visit. |
At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in PBC risk scores based in Global PBC Study Group (GLOBE) score
기간: At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 patients with PBC. Lower GLOBE score predicts lower risk. It is calculated from the following equation: GLOBE score = (0.044378 * age + 0.93982 * LN(total bilirubin/ULN) +(0.335648 * LN(alkaline phosphatase/ULN)) - 2.266708 * albumin /LLN -0.002581 * platelet count per 109/L) + 1.216865 GLOBE scoring system, which calculation is based on serum values of bilirubin, ALP, albumin and platelet count after 1 year of treatment and age at baseline. A high number is indicative of a worse score. |
At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in PBC risk scores based on United Kingdom (UK)-PBC score.
기간: At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
PBC risk score developed by United Kingdom (UK)-PBC Consortium is a scoring system and the calculation is based on laboratory test measurements and upper limits of normal (ULN) for the total bilirubin (BIL12); alanine transaminase or aspartate transaminase (TA12), and alkaline phosphatase (ALP12) after at least 12 months of UDCA, and the laboratory test measurements and lower limits of normal (LLN) for the serum albumin and platelet count in the same timeframe. A high number is indicative of a worse score. |
At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Percentage of participants with LSM ≥15 kPa
기간: At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
Assessed by VCTE using Fibroscan® |
At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Percentage of participants with no worsening of LSM
기간: At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
Assessed by VCTE using Fibroscan® defined as no increase >2kPa from baseline |
At Month 12, and every 12 months up to end of treatment (maximum duration of 3.5 years)
|
|
Percentage of participants with a response in PBC Worst Itch NRS score
기간: Through 6 months up to end of treatment (maximum duration of 3.5 years)
|
Defined as ≥2-point reduction from baseline NRS in participants with a baseline NRS ≥4 |
Through 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Percentage of participants with a response in PBC Worst Itch NRS
기간: Assessed through 6 months up to end of treatment (maximum duration of 3.5 years)
|
Defined as ≥3-point reduction from baseline NRS in participants with a baseline NRS ≥4 |
Assessed through 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in 5D-Itch scale
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
Questionnaire that assesses symptoms in terms of 5 domains: degree, duration, direction, disability and distribution. Participants rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in Patient Global Impression of Severity (PGI-S)
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
A 1-item, 5-point scale designed to assess the participant's impression of disease severity |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Patient Global Impression of Change (PGI-C)
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
A 1-item, 5-point scale designed to assess the participant's impression of change in disease severity since the baseline visit |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in Patient Reported Outcome Measurement Information System (PROMIS) Fatigue Short Form 7a
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
Consists of 7 items that measure both the experience of fatigue and the interference of fatigue on daily activities over the past week. Response options are on a 5-point Likert scale, ranging from 1 to 5. Scores can range from 7 to 35, with higher scores indicating greater fatigue. |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in the Epworth Sleepiness Scale (ESS)
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
Self-administered questionnaire that consists of 8 questions asking to rate how likely it is to fall asleep in different situations commonly encountered in daily life (each question can be scored from 0 to 3 points; '0' indicates no sleepiness, '3' indicates significant sleepiness). It provides a total score which has been shown to relate to the participant's level of daytime sleepiness (total score range 0-24 points). |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in PBC-40 score
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
40-item questionnaire that assesses symptoms across 6 domains: fatigue, emotional and social, cognitive function, general symptoms and itch. Participants respond on a verbal response scale, depending on the section options range from 'never' / 'not at all' / 'strongly disagree' to 'always' / 'very much' / 'strongly agree'. Six items (3/3 in the itch domain, 2/10 in the social domain, and 1/7 in the general symptoms domain) also include a 'does not apply' option. A score for each domain is provided (but a total score is not calculated), with each verbal response scale correlating to a score of 1 to 5 per item (0 to 5 on items with a 'does not apply' option) with 5 being the most affected (greatest burden). The PBC-40 has a 4-week recall period. |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in PBC Worst Itch Numeric Rating Scale (NRS) score
기간: Assessed through 6 months up to end of treatment (maximum duration of 3.5 years)
|
Self-administered patient-reported outcome questionnaire that measures itch intensity. It asks participants to rate the intensity of their Worst Itch on an 11-point scale ranging from 0 (no itch) to 10 (Worst Itch imaginable): - once daily (24-hour recall period) using the eDiary during the screening and initial 2 years of the study, - at the clinic visits (7-day recall period), from Year 3 onwards |
Assessed through 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in EuroQol 5-dimensional 5-level questionnaire (EQ-5D-5L)
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
Self-administered standardised questionnaire that assesses the 5-dimensions of mobility, self-care, usual activities, pain/discomfort, anxiety/depression descriptively (each dimension has 5 levels) and the overall health state via an EQ Visual Analogue Scale (VAS). |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in Work Productivity and Activity Impairment General Health (WPAI-GH)
기간: Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
Questionnaire that measures absenteeism, presenteeism as well as the impairments in unpaid activity because of health problem during the past seven days. It consists of 6 questions: 1=currently employed; 2=hours missed because of health problems; 3=hours missed because of other reasons; 4=hours actually worked; 5=degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6=degree health affected productivity in regular unpaid activities (VAS). |
Assessed at every 6 months up to end of treatment (maximum duration of 3.5 years)
|
|
Time to the first occurrence of each of individual adjudicated clinical outcome events
기간: From baseline until 4 weeks after the last dose of study intervention
|
Among: • All-cause mortality • Liver-related mortality • Liver transplant • MELD-3.0 score ≥15 in participants with baseline MELD score ≤12 • Liver decompensation |
From baseline until 4 weeks after the last dose of study intervention
|
|
Percentage of participants who experience any subsequent adjudicated clinical outcome events after the first occurrence of such an event
기간: From baseline until 4 weeks after the last dose of study intervention
|
Among: • All-cause mortality • Liver-related mortality • Liver transplant • MELD-3.0 score ≥15 in participants with baseline MELD score ≤12 • Liver decompensation |
From baseline until 4 weeks after the last dose of study intervention
|
|
Change from baseline in model for end-stage liver disease (MELD) 3.0 score
기간: From screening until end of treatment (maximum duration of 3.5 years)
|
The MELD 3.0 score is calculated from parameters (sex, creatinine, bilirubin, INR, sodium and albumin) where a high score indicates a greater risk of needing a liver transplant. |
From screening until end of treatment (maximum duration of 3.5 years)
|
|
Change from baseline in Child Pugh grade
기간: From screening until end of treatment (maximum duration of 3.5 years)
|
Child Pugh grade is calculated using bilirubin, albumin, INR, ascites and encephalopathy. A high grade is indicative of worse liver disease. |
From screening until end of treatment (maximum duration of 3.5 years)
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Ipsen Medical Director, Ipsen
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CLIN-60190-454
- 2023 (미국 NIH 보조금/계약)
- 2023-505251-43-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 공유 기간
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 공유 액세스 기준
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .